ARROWHEAD PHARMACEUTICALS IN (ARWR) Fundamental Analysis & Valuation

NASDAQ:ARWR • US04280A1007

Current stock price

74.81 USD
+1.33 (+1.81%)
At close:
74.81 USD
0 (0%)
After Hours:

This ARWR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ARWR Profitability Analysis

1.1 Basic Checks

  • In the past year ARWR was profitable.
  • ARWR had a positive operating cash flow in the past year.
  • In the past 5 years ARWR always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: ARWR reported negative operating cash flow in multiple years.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • ARWR has a better Return On Assets (12.61%) than 94.19% of its industry peers.
  • With an excellent Return On Equity value of 35.58%, ARWR belongs to the best of the industry, outperforming 97.29% of the companies in the same industry.
  • ARWR's Return On Invested Capital of 13.98% is amongst the best of the industry. ARWR outperforms 95.54% of its industry peers.
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROIC 13.98%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • ARWR has a better Profit Margin (18.54%) than 92.83% of its industry peers.
  • Looking at the Operating Margin, with a value of 27.55%, ARWR belongs to the top of the industry, outperforming 95.16% of the companies in the same industry.
Industry RankSector Rank
OM 27.55%
PM (TTM) 18.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ARWR Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ARWR is still creating some value.
  • ARWR has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ARWR has been increased compared to 5 years ago.
  • ARWR has a better debt/assets ratio than last year.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 6.59 indicates that ARWR is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ARWR (6.59) is better than 75.97% of its industry peers.
  • ARWR has a debt to FCF ratio of 1.80. This is a very positive value and a sign of high solvency as it would only need 1.80 years to pay back of all of its debts.
  • ARWR has a better Debt to FCF ratio (1.80) than 93.60% of its industry peers.
  • ARWR has a Debt/Equity ratio of 0.95. This is a neutral value indicating ARWR is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.95, ARWR is doing worse than 75.78% of the companies in the same industry.
  • Although ARWR's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Altman-Z 6.59
ROIC/WACC1.54
WACC9.09%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • A Current Ratio of 3.38 indicates that ARWR has no problem at all paying its short term obligations.
  • ARWR's Current ratio of 3.38 is in line compared to the rest of the industry. ARWR outperforms 41.67% of its industry peers.
  • ARWR has a Quick Ratio of 3.38. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.38, ARWR perfoms like the industry average, outperforming 44.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ARWR Growth Analysis

3.1 Past

  • ARWR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.65%, which is quite impressive.
  • Looking at the last year, ARWR shows a very strong growth in Revenue. The Revenue has grown by 43539.24%.
  • The Revenue has been growing by 56.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%

3.2 Future

  • The Earnings Per Share is expected to grow by 101.11% on average over the next years. This is a very strong growth
  • ARWR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y-4307.25%
EPS Next 2Y-631.46%
EPS Next 3Y-235.86%
EPS Next 5Y101.11%
Revenue Next Year-40.85%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. ARWR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 48.90, which means the current valuation is very expensive for ARWR.
  • ARWR's Price/Earnings ratio is rather cheap when compared to the industry. ARWR is cheaper than 90.12% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. ARWR is valued rather expensively when compared to this.
  • The Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 48.9
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ARWR indicates a rather cheap valuation: ARWR is cheaper than 91.28% of the companies listed in the same industry.
  • ARWR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ARWR is cheaper than 93.60% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.53
EV/EBITDA 28.94
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • ARWR's earnings are expected to decrease with -235.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-631.46%
EPS Next 3Y-235.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARWR Dividend Analysis

5.1 Amount

  • No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARWR Fundamentals: All Metrics, Ratios and Statistics

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (5/1/2026, 8:10:08 PM)

After market: 74.81 0 (0%)

74.81

+1.33 (+1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)02-05
Earnings (Next)05-07
Inst Owners84.39%
Inst Owner Change-0.35%
Ins Owners3.67%
Ins Owner Change-0.5%
Market Cap10.48B
Revenue(TTM)1.09B
Net Income(TTM)202.26M
Analysts80
Price Target84.07 (12.38%)
Short Float %8.92%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.98%
Min EPS beat(2)-14.75%
Max EPS beat(2)26.7%
EPS beat(4)2
Avg EPS beat(4)363.28%
Min EPS beat(4)-20.51%
Max EPS beat(4)1461.66%
EPS beat(8)2
Avg EPS beat(8)69.08%
EPS beat(12)3
Avg EPS beat(12)46.94%
EPS beat(16)4
Avg EPS beat(16)35.01%
Revenue beat(2)1
Avg Revenue beat(2)19.41%
Min Revenue beat(2)-4.15%
Max Revenue beat(2)42.98%
Revenue beat(4)3
Avg Revenue beat(4)433.43%
Min Revenue beat(4)-4.15%
Max Revenue beat(4)1680.09%
Revenue beat(8)3
Avg Revenue beat(8)167.14%
Revenue beat(12)4
Avg Revenue beat(12)110.57%
Revenue beat(16)5
Avg Revenue beat(16)76.26%
PT rev (1m)3.24%
PT rev (3m)8.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.74%
EPS NY rev (1m)-2.19%
EPS NY rev (3m)-2.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.16%
Valuation
Industry RankSector Rank
PE 48.9
Fwd PE N/A
P/S 9.6
P/FCF 32.53
P/OCF 30.87
P/B 18.43
P/tB 18.64
EV/EBITDA 28.94
EPS(TTM)1.53
EY2.05%
EPS(NY)-4.28
Fwd EYN/A
FCF(TTM)2.3
FCFY3.07%
OCF(TTM)2.42
OCFY3.24%
SpS7.79
BVpS4.06
TBVpS4.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.8212 (-84.2%)
Profitability
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROCE 23.92%
ROIC 13.98%
ROICexc 51.35%
ROICexgc 52.33%
OM 27.55%
PM (TTM) 18.54%
GM N/A
FCFM 29.52%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Debt/EBITDA 1.65
Cap/Depr 68.96%
Cap/Sales 1.59%
Interest Coverage 250
Cash Conversion 104.19%
Profit Quality 159.2%
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 6.59
F-Score7
WACC9.09%
ROIC/WACC1.54
Cap/Depr(3y)756.37%
Cap/Depr(5y)612.23%
Cap/Sales(3y)1353.35%
Cap/Sales(5y)819.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
EPS Next Y-4307.25%
EPS Next 2Y-631.46%
EPS Next 3Y-235.86%
EPS Next 5Y101.11%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%
Revenue Next Year-40.85%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%
EBIT growth 1Y148.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-531.29%
EBIT Next 3Y-105.85%
EBIT Next 5Y49.99%
FCF growth 1Y179.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y272.91%
OCF growth 3YN/A
OCF growth 5YN/A

ARROWHEAD PHARMACEUTICALS IN / ARWR Fundamental Analysis FAQ

What is the fundamental rating for ARWR stock?

ChartMill assigns a fundamental rating of 5 / 10 to ARWR.


What is the valuation status of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

ChartMill assigns a valuation rating of 3 / 10 to ARROWHEAD PHARMACEUTICALS IN (ARWR). This can be considered as Overvalued.


How profitable is ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

ARROWHEAD PHARMACEUTICALS IN (ARWR) has a profitability rating of 5 / 10.


What are the PE and PB ratios of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

The Price/Earnings (PE) ratio for ARROWHEAD PHARMACEUTICALS IN (ARWR) is 48.9 and the Price/Book (PB) ratio is 18.43.


What is the expected EPS growth for ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

The Earnings per Share (EPS) of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to decline by -4307.25% in the next year.